GlassScriptPhysician profile
Seif M Saeed
NPI 1598753568
$5,443.36
in general payments reported to CMS, 2019-2025
40 companies · $587 in 2025
The $587 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $531 · 2021: $941 · 2022: $1,055 · 2023: $529 · 2024: $529 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.06 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $684.83 | 2021-2025 | Qulipta |
| Gilead Sciences, INC. | $651.79 | 2021-2024 | Veklury |
| Amgen INC. | $559.40 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.39 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $288.80 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $267.06 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $249.56 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $249.37 | 2019-2021 | |
| Novo Nordisk INC | $247.59 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $217.55 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $205.10 | 2019-2025 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $184.30 | 2020-2025 | Fanapt, Hetlioz |
| Nestle Healthcare Nutrition INC. | $127.25 | 2021 | |
| Janssen Pharmaceuticals, INC | $113.02 | 2019-2022 | |
| Exact Sciences Corporation | $104.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $87.62 | 2019-2025 | Trintellix, Eohilia |
| Sunovion Pharmaceuticals INC. | $80.15 | 2019 | |
| Allergan, INC. | $78.21 | 2019-2020 | |
| Lilly USA, LLC | $73.92 | 2021-2023 | Jardiance, Emgality |
| Alkermes, INC. | $67.87 | 2022-2025 | Vivitrol |
| Ultragenyx Pharmaceutical INC. | $55.92 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $55.49 | 2023-2025 | Eliquis, Cobenfy |
| Merck Sharp & Dohme LLC | $50.79 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.47 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $49.27 | 2019-2024 | Veozah |
| Seqirus USA INC | $48.28 | 2022 | |
| Glaxosmithkline, LLC. | $36.00 | 2024-2025 | Trelegy Ellipta |
| Dexcom, INC. | $30.42 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.39 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $24.31 | 2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $23.82 | 2025 | Zenpep |
| Ucb, INC. | $23.39 | 2024 | Nayzilam |
| Daiichi Sankyo INC. | $19.70 | 2019 | |
| Orthogenrx INC. | $19.22 | 2019 | |
| Supernus Pharmaceuticals, INC. | $18.29 | 2021 | |
| Horizon Therapeutics Plc | $17.94 | 2020 | |
| Lundbeck LLC | $15.33 | 2023 | Rexulti |
| Mylan Specialty L.P. | $15.01 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.33 | 2024 | Quviviq |
| Brainsway USA INC | $14.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seif Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.